Cytogen, Inc. (KOSDAQ:217330)

South Korea · Delayed Price · Currency is KRW

3,055.00

-35.00 (-1.13%)

At close: Sep 11, 2026

Market Cap	70.65B +14.7%
Revenue (ttm)	27.38B +31.6%
Net Income	-10.55B
EPS	-456.81
Shares Out	23.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,146
Open	3,090.00
Previous Close	3,090.00
Day's Range	3,005.00 - 3,090.00
52-Week Range	2,260.00 - 11,200.00
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2010

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 217330

Full Company Profile

Financial Performance

In 2025, Cytogen's revenue was 26.05 billion, an increase of 138.80% compared to the previous year's 10.91 billion. Losses were -12.34 billion, -27.89% less than in 2024.

Financial Statements